Metformin/rosuvastatin - Yuhan Corporation

Drug Profile

Metformin/rosuvastatin - Yuhan Corporation

Alternative Names: Rosuvastatin/metformin - Yuhan; YH 14755; YH-IMD3; YH_IMD3

Latest Information Update: 29 Oct 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Yuhan
  • Class Antihyperglycaemics; Antihyperlipidaemics; Biguanides; Fluorobenzenes; Pyrimidines; Small molecules; Sulfonamides
  • Mechanism of Action AMP activated protein kinase stimulants; Gluconeogenesis inhibitors; HMG-CoA reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Dyslipidaemias; Type 2 diabetes mellitus

Most Recent Events

  • 01 Oct 2015 Phase-III clinical trials in Dyslipidaemias and Type-2 diabetes mellitus in South Korea (PO) (NCT02586129)
  • 30 Sep 2014 Yuhan Corporation completes a phase I trial in Healthy volunteers in South Korea (NCT02125227)
  • 20 May 2014 Phase-I development is ongoing in South Korea
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top